Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed diagnosis of one of the following:
• * Non-Hodgkin's lymphoma
• * Primary or metastatic solid tumor located, by radiography, in at least one of the following sites:
• * Liver
• * Soft tissue
• * Pelvis
• * Other site that is suitable for delayed contrast-enhanced MRI (e.g., peripheral lung field)
• Relapsed or refractory (including unresectable) disease
• * Patients with solid tumors must have failed all curative chemotherapeutic regimens
• * Patients with non-Hodgkin's lymphoma must be refractory to at least 2 standard chemotherapeutic regimens and rituximab
• Not amenable to available conventional therapies AND no standard therapy exists
• Measurable disease
• No prior or concurrent CNS metastases (brain or leptomeningeal)
• No primary intracranial tumor by MRI or CT scan
• No histologically confirmed squamous cell carcinoma of the lung
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• WBC ≥ 3,500/mm\^3
• Absolute neutrophil count ≥ 1,500/mm\^3
• Hemoglobin ≥ 9.0 g/dL
• Platelet count ≥ 100,000/mm\^3
• No severe or uncontrolled hematologic condition
• Hepatic
• Bilirubin ≤1.5 times upper limit of normal (ULN)
• AST and ALT ≤ 2.5 times ULN
• PT and PTT normal
• INR normal
• Hepatitis B surface antigen negative
• Hepatitis C antibody negative
• Renal
• Creatinine ≤ ULN
• Urine protein/creatinine ratio ≤ 1
• No severe or uncontrolled renal condition
• Cardiovascular
• No clinically significant acute electrocardiographic abnormalities
• LVEF normal by echocardiogram or MUGA within the past 12 months if there was prior exposure to anthracyclines
• No untreated or uncontrolled hypertension
• * No blood pressure \> 150/100 mm Hg (despite treatment)
• No isolated systolic hypertension (i.e., systolic blood pressure \> 180 mm Hg on at least 2 determinations \[on separate days\] within the past 3 months)
• No New York Heart Association class II - IV heart disease
• No active coronary artery disease requiring acute medical management
• No angina requiring acute medical management
• No congestive heart failure requiring acute medical management
• No ventricular arrhythmia requiring acute medical management
• No stroke or transient ischemic event within the past 6 months
• No prior or concurrent peripheral vascular disease
• * No angiographically or ultrasonographically documented arterial or venous occlusive event
• * No symptomatic claudication
• No symptomatic orthostatic hypotension
• No other severe or uncontrolled cardiovascular condition
• Pulmonary
• No severe or uncontrolled pulmonary condition
• No pulmonary embolism within the past 6 months
• Immunologic
• HIV negative
• No severe or uncontrolled immunologic condition
• No active current infection requiring antibiotics
• No prior hypersensitivity reaction to any recombinant proteins, including VEGF Trap
• Other
• No severe or uncontrolled gastrointestinal or musculoskeletal condition
• No psychiatric condition or adverse social circumstance that would preclude study participation
• No other condition that would preclude study participation
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective double-barrier contraception during and for 3 months after study treatment
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• See Disease Characteristics
• No prior participation in a VEGF Trap, interleukin-1 Trap, or interleukin-4/13 Trap clinical trial
• At least 3 weeks since prior immunotherapy and recovered
• No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)
• Chemotherapy
• See Disease Characteristics
• At least 3 weeks since prior chemotherapy and recovered
• Endocrine therapy
• No concurrent adrenal corticosteroids except low-dose replacement therapy
• No concurrent systemic hormonal contraceptive agents
• Radiotherapy
• At least 3 weeks since prior radiotherapy and recovered
• Surgery
• At least 3 weeks since prior major or laparoscopic surgery and recovered
• More than 6 months since prior surgical procedure for correction or prophylaxis of peripheral vascular insufficiency or cerebral ischemic events
• Other
• More than 30 days since prior investigational drugs
• No concurrent anticoagulant or antiplatelet drugs (e.g., warfarin, heparin, or aspirin) other than low-dose (1 mg) warfarin for maintaining patency of venous access devices
• No concurrent non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 (COX-2) inhibitors
• No other concurrent anticancer investigational agents
• No other concurrent anticancer therapy